Utility of Genome-Wide Association Study findings: prostate cancer as a translational research paradigm
Article first published online: 23 MAR 2012
© 2012 The Association for the Publication of the Journal of Internal Medicine
Journal of Internal Medicine
Volume 271, Issue 4, pages 344–352, April 2012
How to Cite
Turner, A. R., Kader, A. K. and Xu, J. (2012), Utility of Genome-Wide Association Study findings: prostate cancer as a translational research paradigm. Journal of Internal Medicine, 271: 344–352. doi: 10.1111/j.1365-2796.2012.02522.x
- Issue published online: 23 MAR 2012
- Article first published online: 23 MAR 2012
- Accepted manuscript online: 24 JAN 2012 11:11AM EST
- gene polymorphism;
- molecular medicine;
- risk factors
Abstract. Turner AR, Kader AK, Xu J (Wake Forest University, Winston-Salem, NC; and University of California San Diego, La Jolla, CA; USA). Utility of Genome-Wide Association Study findings: prostate cancer as a translational research paradigm (Review). J Intern Med 2012; 271: 344–352.
Genome-Wide Association Studies have identified thousands of consistently replicated associations between genetic markers and complex disease risk, including cancers. Alone, these markers have limited utility in risk prediction; however, when several of these markers are used in combination, the predictive performance appears to be similar to that of many currently available clinical predictors. Despite this, there are divergent views regarding the clinical validity and utility of these genetic markers in risk prediction. There are valid concerns, thus providing a direction for new lines of research. Herein, we outline the debate and use the example of prostate cancer to highlight emerging evidence from studies that aim to address potential concerns. We also describe a translational framework that could be used to guide the development of a new generation of comprehensive research studies aimed at capitalizing on these exciting new discoveries.